@article{SCI13974,
author = {Rashi Bharat Patel and Ting Li and Zhichao Liao and Jivani Aakash Jaldeepbhai and H. A. Pavanika N. V. Perera and Sujani Kaushalya Muthukuda and Dholiya Hardeep Dhirubhai and Vaibhav Singh and Xiaoling Du and Jilong Yang},
title = {Recent translational research into targeted therapy for liposarcoma},
journal = {Stem Cell Investigation},
volume = {4},
number = {3},
year = {2017},
keywords = {},
abstract = {Liposarcomas (LPS) are among the most common soft tissue sarcomas, originating from adipocytes. Treatment for LPS typically involves surgical resection and radiation therapy, while the use of conventional cytotoxic chemotherapy for unresectable or metastatic LPS remains controversial. This review summarizes the results of recent translational research and trials of novel therapies targeting various genetic and molecular aberrations in different subtypes of LPS. Genetic aberrations such as the 12q13-15 amplicon, genetic amplification of MDM2, CDK4, TOP2A, PTK7, and CHEK1, point mutations in CTNNB1, CDH1, FBXW7, and EPHA1, as the fusion of FUS-DDIT3/EWSR1-DDIT3 are involved in the pathogenesis LPS and represent potential therapeutic candidates. Tyrosine kinase inhibitors targeting MET, AXL, IGF1R, EGFR, VEGFR2, PDGFR-β and Aurora kinase are effective in certain types of LPS. Abnormalities in the PI3K/Akt signaling pathway deregulation of C/EBP-α and its partner PPAR-γ, and the interaction between calreticulin (CRT) and CD47 are also promising therapeutic targets. These promising new approaches may help to supplement existing treatments for LPS.},
issn = {2313-0792}, url = {https://sci.amegroups.org/article/view/13974}
}